1. Volume 11, Issue 4, Pages 331-340 (April 2012)
Prognostic factors for time to treatment failure and time to 12 months of remission for patients with focal epilepsy: post-hoc, subgroup analyses of data from the SANAD trial 
Laura Bonnett, MmathStat, Catrin Tudur Smith, PhD, David Smith, MD, Paula Williamson, PhD, Prof David Chadwick, MD, Prof Anthony G Marson, MD 
The Lancet Neurology 
Volume 11, Issue 4, Pages (April 2012)
DOI: /S (12)
Copyright © 2012 Elsevier Ltd Terms and Conditions

2. Figure 1
Trial profile
*Patients with a time from first seizure to randomisation in the first or last 1% of the variable were removed from the data set.21 † Patients with generalised epilepsy were removed from analyses.
The Lancet Neurology  , DOI: ( /S (12) )
Copyright © 2012 Elsevier Ltd Terms and Conditions

3. Figure 2 Combination of risk factors for time to treatment failure
Bars show 95% CIs. M=male. F=female.
The Lancet Neurology  , DOI: ( /S (12) )
Copyright © 2012 Elsevier Ltd Terms and Conditions

4. Figure 3
Relative hazard ratio plots for age and total number of seizures before randomisation for the time to treatment failure
Hazard ratio estimates with 95% CIs are shown for overall time to treatment failure, for age (A) and total number of seizures (B), and for time to treatment failure because of inadequate seizure control and because of unacceptable adverse events, for age (C) and total number of seizures (D).
The Lancet Neurology  , DOI: ( /S (12) )
Copyright © 2012 Elsevier Ltd Terms and Conditions

5. Figure 4
Relative hazard ratio plots for age, time from first seizure to randomisation, and total number of seizures for time to 12 months of remission
Hazard ratio estimates with 95% CIs are shown for time to 12 months of remission, for age (A), time from first seizure (B), and total number of seizures (C).
The Lancet Neurology  , DOI: ( /S (12) )
Copyright © 2012 Elsevier Ltd Terms and Conditions

6. Figure 5
Combination of risk factors for time to 12 months of remission
Bars show 95% CIs. M=male. F=female.
The Lancet Neurology  , DOI: ( /S (12) )
Copyright © 2012 Elsevier Ltd Terms and Conditions